 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12...5354555657585960616263...208209» |
- Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
Herombopag for Preventing Chemotherapy-Induced Thrombocytopenia in Lymphoma: A Single Center, Randomized Controlled, Phase II Study (Halls G-H (San Diego Convention Center)) - Nov 6, 2024 - Abstract #ASH2024ASH_4170;
All-grade TEAEs were occurred in 20.1% (6/28) of patients in the experimental group versus 17.2% (5/28) in the control group, all were transient and mild. Conclusions : Hetrombopag is an effective and well-tolerated alternative for secondary prevention of CIT in lymphoma, which has demonstrated the capacity to significantly mitigate the severity of CIT, shorten its duration, elevate the nadir platelet value and decrease the incidence of chemotherapy delays.
- Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
Efficacy of Combined Herombopag and Recombinant Human Thrombopoietin Therapy Compared to Monotherapy on Platelet Engraftment after Autologous Hematopoietic Stem Cell Transplantation in Patients (Halls G-H (San Diego Convention Center)) - Nov 6, 2024 - Abstract #ASH2024ASH_4165;
Adding rhTPO does not significantly enhance efficacy compared to herombopag alone. There are no statistically significant differences in engraftment rates, time to engraftment, or post-transplant platelet counts among the groups.
- Hansoh Xinfu (flumatinib) / Jiangsu Hengrui Pharma, Jiangsu Hansoh Pharma, Tasigna (nilotinib) / Novartis, Inhibikase
Similar Efficacy and Distinct Safety Profile of Nilotinib, Dasatinib and Flumatinib in Chronic Myeloid Leukemia Patients Resistant or Intolerant to 1st Line Imatinib (Halls G-H (San Diego Convention Center)) - Nov 6, 2024 - Abstract #ASH2024ASH_4028;
Side effects of concern were rash, bilirubin increasing, cholesterol elevation, thrombotic event and thyroid disease in nilotinib group; pleural effusion, increased pulmonary artery pressure, pericardial effusion, thrombocytopenia, and edema in dasatinib group; increased creatinine and thyroid disease in flumatinib group. Conclusion : The patients intolerant/resistant to imatinib receiving nilotinib, dasatinib or flumatinib as 2L therapy had similar molecular response and survival and suffered different side effects.
- Hansoh Xinfu (flumatinib) / Jiangsu Hengrui Pharma, Jiangsu Hansoh Pharma, Tasigna (nilotinib) / Novartis, Inhibikase
High-Risk (Halls G-H (San Diego Convention Center)) - Nov 6, 2024 - Abstract #ASH2024ASH_4026;
1,632 (78%) patients received initial imatinib therapy; 460 (22%), 2G-TKI therapy (nilotinib, n = 313; dasatinib, n = 78; flumatinib, n = 69). In patients with the high-risk
- AiRuiKa (camrelizumab) / HLB Bio Group
Safety and Efficacy of CD30-Directed Chimeric Antigen Receptor T Cell Therapy Plus Camrelizumab in Patients with Relapsed/Refractory CD30+ Lymphoma (Halls G-H (San Diego Convention Center)) - Nov 6, 2024 - Abstract #ASH2024ASH_3833;
P=N/A
In patients with the high-risk Methods : All patients received lymphodepletion with cyclophosphamide and fludarabine followed by CD30 CAR-T cell infusion (1
- Venclexta (venetoclax) / Roche, AbbVie
Venetoclax Enhances Human ??t Cells Anti-Leukemia Immunity through Metabolic Reprogramming (Halls G-H (San Diego Convention Center)) - Nov 6, 2024 - Abstract #ASH2024ASH_3757;
The ability of venetoclax to potentiate the natural cytotoxic functions of ??T cells and promote a metabolic state conducive to long-lasting cytotoxicity offers a dual mechanism of action that could overcome some of the traditional challenges faced in targeting AML. The convergence of cellular therapy with targeted drug treatment, as evidenced by the efficacy of venetoclax in our research, represents a novel and exciting direction in cancer immunotherapy.
- Pegylated rhG-CSF (mecapegfilgrastim) / Jiangsu Hengrui Pharma
Efficacy and Safety of Single-Dose Versus Split-Dose Mecapegfilgrastim with Etoposide for Autologous Peripheral Blood Stem Cell Mobilization: A Prospective, Randomized Clinical Trial (Halls G-H (San Diego Convention Center)) - Nov 6, 2024 - Abstract #ASH2024ASH_3747;
The split-dose regimen demonstrated a superior optimal mobilization rate at the first collection, suggesting that it may offer a more efficient mobilization approach. The combination of mecapegfilgrastim and high-dose etoposide represents a promising strategy for PBSC mobilization, which merits further investigation.
- Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
Recombinant Human Thrombopoietin Add to IST Combined with Hetrombopag As First-Line Treatment for Na (Halls G-H (San Diego Convention Center)) - Nov 6, 2024 - Abstract #ASH2024ASH_3585;
Several previous studies have shown that IST combined with recombinant human thrombopoietin (rhTPO) or eltrombopag/ hetrombopag can improve the early hematologic response of SAA patients, especially the proportion of good hematologic response (GHR) in the early stage...Here, we report a single-center prospective study of 39 patients with nai?ve severe aplastic anemia treated with porcine ATG and cyclosporine plus hetrombopag combined with rhTPO between March 2023 and April 2024 and evaluate the early outcome of this treatment regimen...The two patients were dependent on the platelet transfusion. In conclusion, adding rh-TPO to standard IST combined with hetrombopag had efficacy in treatment-nai?ve severe aplastic anemia and significantly improved the rapidity and strength of hematologic response.
- HRS-5965 / Jiangsu Hengrui Pharma
Efficacy and Safety of HRS-5965 Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Have Not Received Complement Inhibitors: A Proof-of-Concept, Multicenter, Randomized, Open-Label Study (Halls G-H (San Diego Convention Center)) - Nov 6, 2024 - Abstract #ASH2024ASH_3554;
P2
Both dosages were well-tolerated. This study provides evidence that HRS-5965 might represent a novel treatment option for this patient population.
- Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
Evaluation of the Real-World Efficacy of Hetrombopag for the Treatment of Thrombocytopenia Post Allogeneic Hematopoietic Stem Cell Transplantation (Halls G-H (San Diego Convention Center)) - Nov 6, 2024 - Abstract #ASH2024ASH_3422;
Besides, the platelet response was achieved in 80% (4/5) patients with both aGVHD and viral infections (CMV and/or EBV). Conclusions Our study suggests that hetrombopag is effective in elevating platelet level for the treatment of thrombocytopenia after allo-HSCT in the real world.
- Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
Efficacy and Safety of Hetrombopag in Promoting Platelet Engraftment after Allogeneic Stem Cell Transplantation: A Prospective, Single-Arm Clinical Trail (Halls G-H (San Diego Convention Center)) - Nov 6, 2024 - Abstract #ASH2024ASH_3322;
P4
No abnormality was found in the remaining patients. Conclusions : Compared to rhTPO alone, these results suggested that sequential treatment with rhTPO and HPAG could rapidly promote platelet recovery especially in UCBT.
- Differential in Vitro Sensitivity of BCR::ABL1 Kinase Domain Mutations to Tyrosine Kinase Inhibitors Depending on the p190 or p210 Background (Halls G-H (San Diego Convention Center)) - Nov 6, 2024 - Abstract #ASH2024ASH_2532;
Conclusions : Compared to rhTPO alone, these results suggested that sequential treatment with rhTPO and HPAG could rapidly promote platelet recovery especially in UCBT. The resulting wildtype and 134 mutant Ba/F3 cell lines generated in this way, i.e. 67 cell lines carrying a large spectrum of single and compound mutations in the p190 and p210 background, respectively, were tested in vitro against different concentrations of eight TKIs including imatinib, nilotinib, dasatinib, bosutinib, ponatinib, vamotinib, asciminib, and flumatinib using the CellTiter-Glo
- Hansoh Xinfu (flumatinib) / Jiangsu Hengrui Pharma, Jiangsu Hansoh Pharma
Low-Risk Group Identified By a Refined Prognostic System Integrating Both IKZF1plusgenotyping and MRD Assessment in Adult BCR::ABL1-Positive Acute Lymphoblastic Leukemia (Halls G-H (San Diego Convention Center)) - Nov 6, 2024 - Abstract #ASH2024ASH_2519;
P=N/A
The low-risk group (non-IKZF1plus/MRD-), for the first time, was identified in adult BCR : : ABL1+ ALL. In the era of TKI combined with chemotherapy, it also suggested that allo-HSCT should be spared for the low-risk group, but is recommended for intermediate-risk and high-risk groups if eligible.
- Nailike (olverembatinib) / Takeda
Olverembatinib As Second-Line (2L) Therapy in Patients (pts) with Chronic Phase-Chronic Myeloid Leukemia (CP-CML) (Harbor Ballroom DEFG (Manchester Grand Hyatt San Diego)) - Nov 6, 2024 - Abstract #ASH2024ASH_1706;
P2
Conclusions This is the first study report of olverembatinib in 2L CP-CML treatment. Olverembatinib may provide an effective and safe 2L treatment option for pts with CP-CML, especially those failing on 1L 2G TKIs.
- Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
Hetrombopag Added to Immunosuppressive Therapy in First-Line Treatment of Severe Aplastic Anemia: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial (Room 11 (San Diego Convention Center)) - Nov 6, 2024 - Abstract #ASH2024ASH_1572;
P2, P3
Randomization was stratified based on the source of ATG (rabbit or pig-derived)...These findings support hetrombopag as an effective and safe therapy for SAA patients ineligible for HSCT. Further studies are necessary to assess the long-term efficacy and safety of this treatment approach.
- ||| HRS9950 / Jiangsu Hengrui Pharma
Trial completion, Enrollment change: Safety, Tolerability, Pharmacokinetics(PK), Pharmacodynamics(PD) and Food Effect of HRS9950 in Healthy and CHB Subjects (clinicaltrials.gov) - Nov 5, 2024
P1, N=146, Completed, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Further studies are necessary to assess the long-term efficacy and safety of this treatment approach. Not yet recruiting --> Completed | N=104 --> 146
- || HRS-5965 / Jiangsu Hengrui Pharma
New P1 trial: HRS-5965-103: Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HRS-5965 in Subjects With Hepatic Impairment (clinicaltrials.gov) - Nov 5, 2024
P1, N=28, Not yet recruiting, Sponsor: Chengdu Suncadia Medicine Co., Ltd.
- | AiRuiKa (camrelizumab) / HLB Bio Group, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion: Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - Nov 5, 2024
P2, N=39, Completed, Sponsor: Nanfang Hospital, Southern Medical University
Not yet recruiting --> Completed | N=104 --> 146 Recruiting --> Completed
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P3 trial: Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy. (clinicaltrials.gov) - Nov 5, 2024
P3, N=586, Recruiting, Sponsor: Sun Yat-sen University
- | AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment open: NACI-CERV-005: Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer (clinicaltrials.gov) - Nov 4, 2024
P2, N=40, Recruiting, Sponsor: Tongji Hospital
Recruiting --> Completed Not yet recruiting --> Recruiting
- Insights From Randomized Controlled Trials on the Efficacy and Safety of Pharmacological Therapies for Differentiated Thyroid Cancer: A Systematic Review () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_2014;
Despite modest progress in the general DTC population, lenvatinib has revolutionized RAIR-DTC treatment by delivering a higher response rate and extended survival, although with a higher adverse event risk. Therefore, further DTC research needs to be conducted both in the broader population and in the RAIR-DTC population.
- Leveraging External Priors to Address Population Variability in a Network Meta-Analysis: A Case Study in Advanced Esophageal Squamous Cell Carcinoma () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_955;
After accounting for Asian population differences , pembrolizumab showed highest reduction in the risk of mortality (HR=0.64, 36%), followed by tislelizumab (34%), camrelizumab (29%), sintilumab (29%), and nivolumab (24%). Our results provide a robust approximation of a NMA
- Systematic Literature Review (SLR) of Disease Burden Related to First-Line (1L) Unresectable, Locally Advanced, or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) () - Nov 4, 2024 - Abstract #ISPOREU2024ISPOR_EU_232;
Our results provide a robust approximation of a NMA Model parameters varied across CUAs, and incremental cost-utility ratios (ICURs) for IO agents ranged widely from $13,209
- | Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
Journal, HEOR: The effect of hetrombopag combined with conventional treatment on immune function and quality of life in patients with severe aplastic anemia. (Pubmed Central) - Nov 4, 2024
After receiving the treatment, all scores of SF-36 domains in both groups were higher than before treatment, particularly with higher scores in the experimental group (P?<?0.05). Hetrombopag combined with conventional treatment improved the immune function and hematopoiesis of patients with SAA.
- | AiRuiKa (camrelizumab) / HLB Bio Group
Journal: Sustained Remission of Relapsed Extranodal NK/T-Cell Lymphoma After Treatment With Camrelizumab Plus P-GEMOX and Autologous Stem Cell Transplantation: A Case Report. (Pubmed Central) - Nov 4, 2024
Hetrombopag combined with conventional treatment improved the immune function and hematopoiesis of patients with SAA. No abstract available
- || Irene (pyrotinib) / Jiangsu Hengrui Pharma
Trial primary completion date: MA-BC-II-018: Pyrotinib in Combination with Neoadjuvant Chemotherapy in HR+/HER2-, HER4 High Expression Breast Cancer Patients: a Phase II Trial (clinicaltrials.gov) - Nov 4, 2024
P2, N=140, Recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
No abstract available Trial primary completion date: Dec 2023 --> Dec 2025
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P3 trial: RALLY: Adebrelimab Combined with Chemotherapy and Thoracic Radiotherapy for First-line Treatment of ES-SCLC (clinicaltrials.gov) - Nov 4, 2024
P3, N=524, Not yet recruiting, Sponsor: Jinming Yu
- |||||||||| ruzaltatug rezetecan (SHR-A2009) / Jiangsu Hengrui Pharma
New P3 trial: A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC (clinicaltrials.gov) - Nov 4, 2024
P3, N=500, Not yet recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Journal, Metastases: Camrelizumab combined with gemcitabine and apatinib in treating advanced PD-L1-positive biliary tract cancers. (Pubmed Central) - Nov 4, 2024
The most frequent grade 3 or 4 treatment-related adverse event was neutropenia (n?=?4, 29%). The combination of camrelizumab, gemcitabine, and apatinib showed promising efficacy and acceptable safety in patients with advanced PD-L1-positive biliary tract cancer.
- | AiRuiKa (camrelizumab) / HLB Bio Group
Trial completion date, Trial termination, Trial primary completion date: Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel As Second-line Treatment in Advanced Gastric Cancer (clinicaltrials.gov) - Nov 4, 2024
P2, N=58, Terminated, Sponsor: Huazhong University of Science and Technology
The combination of camrelizumab, gemcitabine, and apatinib showed promising efficacy and acceptable safety in patients with advanced PD-L1-positive biliary tract cancer. Trial completion date: Jun 2023 --> Nov 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Mar 2023 --> Nov 2023; slow recruitment forcing early suspension of screening and enrollment
- |||| HRS-7535 / Kailera Therapeutics
New P2 trial: Long-term Efficacy and Safety of HRS-7535 Tablets in Obese Subjects (clinicaltrials.gov) - Nov 4, 2024
P2, N=180, Not yet recruiting, Sponsor: Shandong Suncadia Medicine Co., Ltd.
- |||||||||| HRS-7535 / Kailera Therapeutics
New P3 trial: A Study of HRS-7535 Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequately Controlled With Diet and Exercise (clinicaltrials.gov) - Nov 4, 2024
P3, N=272, Not yet recruiting, Sponsor: Shandong Suncadia Medicine Co., Ltd.
- | trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
Trial primary completion date: BC-NEO-IIT-SHR-A1811: A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer (clinicaltrials.gov) - Nov 4, 2024
P2, N=66, Recruiting, Sponsor: Henan Cancer Hospital
Trial completion date: Jun 2023 --> Nov 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Mar 2023 --> Nov 2023; slow recruitment forcing early suspension of screening and enrollment Trial primary completion date: May 2024 --> Dec 2024
- |||||| ribupatide injection (HRS9531 injection) / Kailera Therapeutics
Enrollment open, Monotherapy: A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination With SGLT2 Inhibitors in Participants With Type 2 Diabetes (clinicaltrials.gov) - Nov 4, 2024
P3, N=840, Recruiting, Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
Trial primary completion date: May 2024 --> Dec 2024 Not yet recruiting --> Recruiting
- || AiRuiKa (camrelizumab) / HLB Bio Group
Retrospective data, Review, Journal, Metastases: Camrelizumab Combined with Transcatheter Arterial Chemoembolization for Intermediate or Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-analysis. (Pubmed Central) - Nov 2, 2024
This study demonstrated the efficacy and safety of combining TACE with camrelizumab in treating patients with advanced HCC, providing valuable evidence for its prospective clinical application. However, due to the limited availability of clinical data, it is essential to design larger-scale and multi-center clinical randomized controlled trials in the future to validate and confirm these findings definitively.
- || AiRuiKa (camrelizumab) / HLB Bio Group
P2 data, Journal, PD(L)-1 Biomarker: [18F]AlF-NOTA-FAPI-04 PET/CT for Predicting Pathologic Response of Resectable Esophageal Squamous Cell Carcinoma to Neoadjuvant Camrelizumab and Chemotherapy: A Phase II Clinical Trial. (Pubmed Central) - Nov 2, 2024
P2
Changes in SUVmax (AUC, 0.81; P = 0.0116), SUVpeak (AUC, 0.82; P = 0.0097), SUVmean (AUC, 0.81; P = 0.0116), and TBRmean (AUC, 0.74; P = 0.0489) also were significant predictors of the pathologic response to nCC, with sensitivities and specificities in similar ranges. 18F-FAPI PET/CT parameters after treatment and their changes from baseline can predict the pathologic response to nCC in LA-ESCC participants.
- || AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
P2 data, Journal, Checkpoint inhibition, Metastases: Efficacy and safety of camrelizumab plus apatinib in patients with advanced esophageal squamous cell carcinoma previously treated with immune checkpoint inhibitors (CAP 02 Re-challenge): A single-arm, phase II study. (Pubmed Central) - Nov 2, 2024
18F-FAPI PET/CT parameters after treatment and their changes from baseline can predict the pathologic response to nCC in LA-ESCC participants. This study showed that the confirmed ORR was modest and did not reach clinically meaningful improvement for patients with ESCC who were previously treated with ICIs, with a manageable safety profile.
- Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
Trastuzumab Combined with Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-Pathological Complete Response HER2-Positive Early Breast Cancer Following Neoadjuvant Therapy: A Multicenter Phase II Study (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_2171;
- AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
A phase I, prospective exploratory clinical study of neoadjuvant pyrotinib plus trastuzumab, dalpiciclib, and letrozole for patients with HR-positive, HER2-positive early or locally advanced breast cancer (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_2170;
- Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche
Efficacy and Safety of Pyrotinib Combined with Trastuzumab and Aromatase Inhibitor in Neoadjuvant Treatment of HER2+/HR+ Breast Cancer: A Single-Arm, Multi-Center Phase II Exploratory Study (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_2109;
- Irene (pyrotinib) / Jiangsu Hengrui Pharma, Cipterbin (inetetamab) / 3SBio
A prospective, open-label, single-arm phase II clinical study of inetetamab in combination w/ pyrotinib & albumin-bound paclitaxel for neoadjuvant treatment of patients with HER2+ early & locally advanced breast cancer: updates on clinical trial (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_2106;
- Irene (pyrotinib) / Jiangsu Hengrui Pharma, Herceptin (trastuzumab) / Roche, Aidixi (disitamab vedotin) / Pfizer
RC48-ADC (Disitamab vedotin, a HER2-directed antibody-drug conjugate) in Combination with Pyrotinib for Trastuzumab-treated HER2-Positive Recurrent or Metastatic Breast Cancer: A Phase Ib/II Study (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_2050;
- Irene (pyrotinib) / Jiangsu Hengrui Pharma, Cipterbin (inetetamab) / 3SBio
Real-World Treatment Patterns and Clinical Outcomes of Inetetamab combined with pyrotinib plus chemotherapy in Her-2 negative metastatic breast cancer patients : a multi-center retrospective study (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_2040;
- Irene (pyrotinib) / Jiangsu Hengrui Pharma, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Trastuzumab deruxtecan combined with pyrotinib in first-line HER2-positive unresectable or metastatic breast cancer: an exploratory, multi-center, single-arm, phase Ib/II study (TROPHY) (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_2035;
- Cipterbin (inetetamab) / 3SBio
Inetetamab-base regimens for patients with HER2-positive metastatic breast cancer and brain metastases: a real-world retrospective study (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_2034;
- Irene (pyrotinib) / Jiangsu Hengrui Pharma, Cipterbin (inetetamab) / 3SBio, Herceptin (trastuzumab) / Roche
A prospective, multicenter, single-arm clinical study of inetetamab combined with pyrotinib and capecitabine/vinorelbine in the treatment of HER2-positive metastatic breast cancer resistant to previous trastuzumab treatment (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_2033;
- GQ1001 / GeneQuantum Healthcare, Irene (pyrotinib) / Jiangsu Hengrui Pharma
Pharmacokinetic profile and preliminary efficacy of GQ1001, a next generation HER2-targeting ADC, combined with pyrotinib in pretreated patients with HER2-positive metastatic breast cancer: A phase 1b clinical trial (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_2028;
- Cipterbin (inetetamab) / 3SBio
Efficacy and safety of inetetamab-containing regimens in patients with HER2-positive metastatic breast cancer in first-line/second-line setting (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1988;
- AiRuiKa (camrelizumab) / HLB Bio Group
Neoadjuvant camrelizumab plus chemotherapy (chemo) for early or locally advanced triple-negative breast cancer (TNBC): a randomized, double-blind, phase 3 trial. (Hall 1) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1903;
- trastuzumab vedotin (MRG002) / Lepu Med
Efficacy and Safety of MRG002 in Prior TKI-Treated HER2 Positive Breast Cancer Patients: A Single Arm, Open Label, Multicenter, Phase II Study (Halls 2-3) - Nov 1, 2024 - Abstract #SABCS2024SABCS_1822;